AU2001278428A1 - Macrolides - Google Patents

Macrolides

Info

Publication number
AU2001278428A1
AU2001278428A1 AU2001278428A AU7842801A AU2001278428A1 AU 2001278428 A1 AU2001278428 A1 AU 2001278428A1 AU 2001278428 A AU2001278428 A AU 2001278428A AU 7842801 A AU7842801 A AU 7842801A AU 2001278428 A1 AU2001278428 A1 AU 2001278428A1
Authority
AU
Australia
Prior art keywords
macrolides
macrolactam
pimecrolimus
epimerization
concomitant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278428A
Other languages
English (en)
Inventor
Gerhard Fleissner
Helmut Hacker
Ernst Kusters
Gerhard Penn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001278428A1 publication Critical patent/AU2001278428A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
AU2001278428A 2000-05-22 2001-05-21 Macrolides Abandoned AU2001278428A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0012383 2000-05-22
GBGB0012383.6A GB0012383D0 (en) 2000-05-22 2000-05-22 Organic compounds
PCT/EP2001/005836 WO2001090110A1 (en) 2000-05-22 2001-05-21 Macrolides

Publications (1)

Publication Number Publication Date
AU2001278428A1 true AU2001278428A1 (en) 2001-12-03

Family

ID=9892108

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278428A Abandoned AU2001278428A1 (en) 2000-05-22 2001-05-21 Macrolides

Country Status (15)

Country Link
US (1) US6706727B1 (ja)
EP (1) EP1289997B1 (ja)
JP (2) JP4043239B2 (ja)
CN (1) CN1229381C (ja)
AT (1) ATE257481T1 (ja)
AU (1) AU2001278428A1 (ja)
CA (1) CA2405593C (ja)
DE (1) DE60101739T2 (ja)
DK (1) DK1289997T3 (ja)
ES (1) ES2214436T3 (ja)
GB (1) GB0012383D0 (ja)
HK (1) HK1054945A1 (ja)
PT (1) PT1289997E (ja)
TR (1) TR200400723T4 (ja)
WO (1) WO2001090110A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618952D0 (en) * 1996-09-11 1996-10-23 Sandoz Ltd Process
CA2442969A1 (en) * 2001-05-09 2002-11-14 Novartis Ag Methods for selective immunomodulation using pimecrolimus
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
JP2005533604A (ja) * 2002-07-25 2005-11-10 アバンテック バスキュラー コーポレーション 治療薬を送達する装置とこれに関する方法
EP1740168A2 (en) * 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
GT200500282A (es) * 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
EP1817315A1 (en) * 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Processes for producing crystalline macrolides
CN104250255B (zh) * 2013-06-28 2016-05-25 北京大学 一种柔性内酰胺类大环分子及其制备方法
WO2018202733A1 (en) * 2017-05-01 2018-11-08 Meda Pharma Gmbh & Co. Kg Process to convert crude ascomycin into purified pimecrolimus
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
JP3362394B2 (ja) * 1995-09-19 2003-01-07 藤沢薬品工業株式会社 エアゾール組成物
US6384073B1 (en) * 1998-02-23 2002-05-07 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for treating glaucoma

Also Published As

Publication number Publication date
TR200400723T4 (tr) 2004-06-21
DE60101739D1 (de) 2004-02-12
CN1430620A (zh) 2003-07-16
WO2001090110A1 (en) 2001-11-29
EP1289997A1 (en) 2003-03-12
CA2405593A1 (en) 2001-11-29
ATE257481T1 (de) 2004-01-15
GB0012383D0 (en) 2000-07-12
JP2007254483A (ja) 2007-10-04
CA2405593C (en) 2009-12-22
HK1054945A1 (en) 2003-12-19
CN1229381C (zh) 2005-11-30
EP1289997B1 (en) 2004-01-07
PT1289997E (pt) 2004-05-31
JP2003534345A (ja) 2003-11-18
DK1289997T3 (da) 2004-05-10
DE60101739T2 (de) 2004-12-09
ES2214436T3 (es) 2004-09-16
US6706727B1 (en) 2004-03-16
JP4043239B2 (ja) 2008-02-06

Similar Documents

Publication Publication Date Title
IL129318A0 (en) Use of 1-benzyl-3- (substituted hetaryl)- fused pyrazole derivatives
GB0007405D0 (en) Compounds
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
CA2247848A1 (en) Nitric oxide donors capable of reducing toxicity from drugs
NZ325837A (en) Carbamoyloxy derivatives of mutiline and their use as antibacterials
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
AU2001278428A1 (en) Macrolides
AU2002222296A1 (en) Macrolide antibiotics
BG103947A (en) Derivatives of 9-oxymerythromycin
MY137156A (en) Dual nk1/nk3 derivatives
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
NZ503897A (en) 3,6-hemiketals from the class of 9a-azalides
ES2164704T3 (es) Derivados en posicion 36 de rifamicinas y su uso como agentes antimicrobianos.
NZ333926A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
ES8701193A1 (es) Un procedimiento para preparar derivados de acido griseolico
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
ATE311403T1 (de) Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen
CA2380455A1 (en) 9a-azalides with antibacterial activity
UA41880C2 (uk) Серотонінергічні похідні ерголіну і фармацевтична композиція
IL116646A0 (en) Antifungal fusacandins
YU5302A (sh) Derivati streptogramina, njihovo dobivanje i smeše koje ih sadrže